Johannes Gutenberg University Mainz

Running trials

• Recruiting

  Early Feasibility Study of the Edwards APTURE Transcatheter Shunt System

  NCT07858799· Edwards Lifesciences· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

  NCT06804161· Phase 3· Prof. Dr. med. Ingo Eitel· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Replimune, Inc.· Source

• Recruiting

  Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

  NCT06223711· Phase 2· Universität des Saarlandes· Source

• Recruiting

  A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

  2022-502959-54-00· Phase 3· Dizal Pharmaceutical Co. Ltd.· Source

• Recruiting

  Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS

  2024-512320-11-00· Phase 3· Medical Center - University Of Freiburg· Source

• Active, not recruiting

  ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

  NCT05686317· Edwards Lifesciences· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma

  2022-501180-40-00· Phase 3· GPOH gGmbH· Source

• Active, not recruiting

  TRISCEND II Pivotal Trial

  NCT04482062· Edwards Lifesciences· Source

• Recruiting

  International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine

  2022-501454-11-00· Phase 3· GPOH gGmbH· Source

• Active, not recruiting

  Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

  NCT03235245· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

  NCT05776459· Phase 2· AudioCure Pharma GmbH· Source

• Recruiting

  Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)

  NCT05092984· Phase 3· University Hospital, Strasbourg, France· Source

• Completed

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

  NCT04039607· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Assessing Health-related Quality of Life in Sarcoma Patients

  NCT04071704· The Netherlands Cancer Institute· Source

• Completed

  CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System

  NCT03699345· Edwards Lifesciences· Source

• Recruiting

  Vercise™ DBS Dystonia Prospective Study

  NCT02686125· Boston Scientific Corporation· Source

• Recruiting

  Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

  NCT02071134· Boston Scientific Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Childhood cancers18 works · 4 trials
• Frontotemporal dementia11 works · 0 trials
• Mantle cell lymphoma9 works · 0 trials
• Coeliac disease9 works · 0 trials
• Peripheral artery disease8 works · 0 trials
• Myeloproliferative neoplasms7 works · 1 trial